Related Experiment Videos
Treatment and visual prognosis in Behçet's disease
The British Journal of Ophthalmology
|August 1, 1986
Summary
Behçet's disease often affects both eye segments within two years, leading to vision loss in most patients despite treatment. Steroids and immunosuppressants help manage inflammation but don't guarantee visual recovery.
Area of Science:
- Ophthalmology
- Rheumatology
- Immunology
Background:
- Behçet's disease is a chronic inflammatory disorder with diverse systemic manifestations.
- Ocular involvement is a common and potentially sight-threatening complication of Behçet's disease.
Purpose of the Study:
- To analyze the long-term clinical course and visual outcomes of patients with ocular Behçet's disease.
- To evaluate the efficacy of steroid and cytotoxic-immunosuppressive treatments on ocular inflammation and visual prognosis.
Main Methods:
- Longitudinal observational study of 49 patients diagnosed with ocular Behçet's disease over a decade.
- Detailed monitoring of ocular involvement (anterior/posterior segments, hypopyon), treatment responses, and visual acuity.
- Analysis of treatment regimens including corticosteroids and cytotoxic-immunosuppressive drugs.
Main Results:
- Bilateral ocular segment involvement occurred within two years in all patients.
- Sterile hypopyon was observed in 17 patients; corneal/scleral involvement was notably absent.
- Initial response to steroids was common, but 42 patients required cytotoxic-immunosuppressive drugs due to steroid resistance.
- Despite treatment, 74% of affected eyes experienced loss of useful visual acuity 6-10 years post-onset.
Conclusions:
- Ocular Behçet's disease typically progresses to bilateral involvement and significant visual impairment.
- While current treatments manage inflammation, their long-term impact on visual prognosis remains uncertain.
- Intensive monitoring and multimodal therapy are crucial for managing this sight-threatening condition.